The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 164:346-a, February 2007
doi: 10.1176/appi.ajp.164.2.346-a
© 2007 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by SHARFSTEIN, S. S.
* Search for Related Content
PubMed
* Articles by SHARFSTEIN, S. S.
Related Collections
* Other Ethics Issues

Letter to the Editor

Dr. Sharfstein Replies

STEVEN S. SHARFSTEIN, M.D.
Towson, Md.

To The Editor: In my Presidential Address, I supported and acknowledged the important contributions of the pharmaceutical industry, whose products have, in my words, "transformed the outcomes for millions of psychiatric patients." In discussing the difficult implementation of Medicare Part D, I bemoaned the unacceptable gaps in access to effective drugs. I confronted Tom Cruise and Scientology on the Today Show when he attacked psychiatry and asserted that "there is no such thing as a chemical imbalance." I agree with Dr. Clary and colleagues that the pharmaceutical industry is an important partner for progress with our profession. However, I take exception to the implication that our partnership must be cheek-to-cheek.

The marketing of medications through millions of dollars in gifts, free trips, meaningless surveys, and other enticements is wrong. It also generates distrust among our patients and drives up costs, as less expensive but equally therapeutic alternative medications fall from routine use.

Too close a relationship with the pharmaceutical industry exacerbates concerning trends in the medical marketplace. Increasingly, psychiatrists are seen as pill pushers, with the result that we are reimbursed for our pharmacologic expertise and very little else. Another unfortunate result (for everyone) is that our profession has less credibility to stand up and object to unnecessary black box warnings.

I have never questioned the ethics and values of psychiatrists who work for pharmaceutical companies. However, the fact that the profit-making motives of industry come into conflict with professional ethics is amply documented and should come as no surprise to the authors. How we work together for the good of patients is the challenge that we face together.





This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by SHARFSTEIN, S. S.
* Search for Related Content
PubMed
* Articles by SHARFSTEIN, S. S.
Related Collections
* Other Ethics Issues


Get information about faster international access.

Privacy Policy

Copyright © 2007 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org